as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹3,850.3
Change
+8.5 (0.22%)
Open
₹3,838.0
Prev. Close
₹3,841.8
Day High
₹3,859.9
Day Low
₹3,801.2
Volume Analysis
Traded
12,312
Delivered
6,816
Delivery %
55.36%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Low operating margin (-12.0%)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,931.76 | ₹3,895.83 | ₹3,873.06 | ₹3,837.13 | ₹3,814.36 | ₹3,778.43 | ₹3,755.66 |
| Fibonacci | ₹3,895.83 | ₹3,873.41 | ₹3,859.55 | ₹3,837.13 | ₹3,814.71 | ₹3,800.85 | ₹3,778.43 |
| Camarilla | ₹3,866.44 | ₹3,861.06 | ₹3,855.68 | ₹3,837.13 | ₹3,844.92 | ₹3,839.54 | ₹3,834.16 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-21.68%
1 Week
-0.36%
1 Month
+2.55%
3 Months
-22.66%
6 Months
-17.57%
1 Year
-23.43%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹825.92
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
33.47%
Net margin 44.25% × asset turnover 0.62x × equity multiplier 1.22x
Company Overview
Sector
Healthcare
Market Cap
₹17,601 Cr
P/E (TTM)
115.0
ROE
19.8%
Book Value
₹302.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Pfizer Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Financial Strength (100/100), while Valuation (8/100) is the weakest area to weigh before deciding. Notably: Low operating margin (-12.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
58/100 — AverageData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 33.2%
- −Stock is trading at 12.7 times its book value
- −Earnings include an other income of Rs.512 Cr.
- −Working capital days have increased from 60.8 days to 135 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Pfizer submitted Regulation 74(5) compliance certificate for quarter ended September 30, 2026.
Copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.
Trading window closed from September 30, 2026 until 48 hours after half-year results.
Source: BSE regulatory filings, via Screener.in.
Profit & Loss (Yearly)
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Sales + | 664 | 676 | 678 |
| Expenses + | 537 | 815 | 760 |
| Operating Profit | 127 | -139 | -82 |
| OPM % | 19.0% | -21.0% | -12.0% |
| Other Income + | 48 | 600 | 512 |
| Interest | 0 | 0 | 0 |
| Depreciation | 13 | 10 | 11 |
| Profit before tax | 163 | 451 | 419 |
| Tax % | 35.0% | 25.0% | 29.0% |
| Net Profit + | 106 | 340 | 300 |
| EPS in Rs | 36 | 114 | 100 |
| Dividend Payout % | 63.0% | 24.0% | 12.0% |
| Sales growth | — | 2 | 0 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Reserves | 376 | 620 | 871 |
| Borrowings + | 0 | 0 | 0 |
| Other Liabilities + | 240 | 218 | 197 |
| Total Liabilities | 646 | 867 | 1,098 |
| Fixed Assets + | 65 | 60 | 51 |
| CWIP | 2 | 10 | 32 |
| Investments | 0 | 0 | 0 |
| Other Assets + | 579 | 797 | 1,014 |
| Total Assets | 646 | 867 | 1,098 |
| Equity Capital | 30 | 30 | 30 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Cash from Operating Activity + | 123 | 17 | 238 |
| Cash from Investing Activity + | 7 | 232 | -79 |
| Cash from Financing Activity + | -34 | -76 | -95 |
| Net Cash Flow | 97 | 173 | 64 |
| Free Cash Flow | 120 | 283 | 213 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 148 | -93 | -446 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 17.87% | 17.42% | 17.0% | 16.5% | 16.54% | 16.79% | 16.45% | 16.37% | 16.32% | 16.36% | 16.62% | 16.93% |
| Promoters | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| FII | 3.03% | 3.32% | 3.22% | 3.54% | 2.74% | 2.18% | 2.4% | 2.6% | 2.71% | 2.81% | 1.65% | 1.63% |
| DII | 15.15% | 15.32% | 15.83% | 16.03% | 16.8% | 17.1% | 17.23% | 17.11% | 17.05% | 16.89% | 17.8% | 17.52% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Pfizer Ltd (this stock) | 17,601 | 115.0 | 12.74 | 19.8% |
| Cohance Lifesciences Ltd | 17,511 | 359.0 | 4.49 | 4.89% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
| Alivus Life Sciences Ltd | 17,803 | 50.6 | — | — |
| Caplin Point Lab Ltd. | 17,863 | 25.9 | 4.58 | 20.9% |
| Syngene International Ltd | 17,935 | 67.5 | 3.7 | 7.78% |
| Molbio Diagnostics Ltd | 17,111 | 236.0 | 11.89 | 15.6% |
Which Mutual Funds Hold Pfizer Ltd?
Frequently Asked Questions about Pfizer Ltd
Pfizer Ltd (PFIZER) closed at ₹3,850.3 on NSE on 19 November 2026, up 8.5 (0.22%) from the previous close.
Pfizer Ltd trades on the NSE (National Stock Exchange of India) under the symbol PFIZER.
Pfizer Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 115.0.
Pfizer Ltd has a dividend yield of 1.95%.
Pfizer Ltd's 52-week high is ₹5,296.0 and its 52-week low is ₹3,589.0.
Pfizer Ltd has a market capitalisation of ₹17,601 crore.
Pfizer Ltd has a TopFund Quality Score of 58/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Pfizer Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.